|
GB202102384D0
|
|
Enzyme inhibitors
|
|
GB202101735D0
|
|
Solid forms of a plasma kallikrein inhibitor and salts thereof
|
|
GB202018970D0
|
|
Enzyme inhibitors
|
|
IL274557D0
|
|
Dosage forms comprising a plasma kallikrein inhibitor
|
|
PH12020500246A1
|
|
Pharmaceutical compositions
|
|
GB201918994D0
|
|
Treatments of diabetic macular edema and impaired visual acuity
|
|
GB201918032D0
|
|
New polymorphs
|
|
WO2021032935A1
|
|
Enzyme inhibitors
|
|
WO2021032936A1
|
|
Enzyme inhibitors
|
|
WO2021032934A1
|
|
Enzyme inhibitors
|
|
WO2021032933A1
|
|
Enzyme inhibitors
|
|
WO2021028645A1
|
|
Plasma kallikrein inhibitors
|
|
GB201910125D0
|
|
Treatments of angioedema
|
|
GB201910116D0
|
|
Treatments of hereditary angioedema
|
|
GB201909694D0
|
|
Method for preparing tablets comprising a plasma kallikrein inhibitor, and the resultimg tablet
|
|
TW201925188A
|
|
Enzyme inhibitors
|
|
GB201721515D0
|
|
Dosage forms comprising a plasma kallikrein inhibtor
|
|
GB201719989D0
|
|
Enzyme inhibitors
|
|
GB201719882D0
|
|
Solid forms of a plasma kallikrein inhibitor and salts thereof
|
|
GB201719881D0
|
|
Solid forms of plasma kallikrein inhibitor and salts thereof
|
